Clinical Trials Browser

Phase 3 × Nausea × Aprepitant × Clear all

NCT02116530 2025-01-28

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Phase 3 Completed

401 enrolled 14 charts

Other hematologic neoplasm

Nausea, Vomiting, Hematologic Neoplasms

NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Phase 3 Completed

52 enrolled 11 charts

Nausea, Vomiting, Neoplasms, Plasma Cell

NCT01661335 2021-03-23

Efficacy of Aprepitant (Emend®) in Children

Phase 3 Completed

Nausea, Neoplasms, Vomiting

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Phase 3 Completed

Breast Neoplasms, Nausea, Vomiting

NCT00475085 2015-11-10

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Phase 3 Completed

1,021 enrolled 10 charts

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male, Inflammatory Breast Neoplasms